RxDoctor Payments Data

Valerie Defoor

Nurse Practitioner · Toccoa, GANPI 1235734344

Payments from drug & device makers

$753in general payments, 2019–2025

Across 38 payments — averaging $19.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$148
  • AstraZeneca$137
  • Indivior Inc.$91
  • Boehringer Ingelheim$80
  • Bayer$42
  • Novo Nordisk$36
  • plus $219 from 10 others

What the payments were for

  • Food & beverage$753100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$753 in reported general payments places this provider in the 70th percentile of 3,328 nurse practitioner providers in Georgia.

See all nurse practitioner providers in Georgia

Medicare billing

Part B allowed, 2024
$60,671
Medicare patients
294
Services billed
2,857

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide21$20,836
JardianceEmpagliflozin18$13,989
EliquisApixaban19$11,799
Nebivolol Hcl11$729
Albuterol Sulfate HfaAlbuterol Sulfate30$691
Gabapentin29$685
SynthroidLevothyroxine Sodium13$664
Fluticasone Propionate71$612
Ondansetron OdtOndansetron42$440
Losartan Potassium30$416
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav68$400
Metoprolol Succinate40$378
Famotidine52$371
Duloxetine Hcl23$366
Pantoprazole Sodium28$358

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$36$20,83621 claims
Boehringer IngelheimJardiance$80$13,98918 claims
PfizerEliquis$16$11,79919 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,328 nurse practitioner providers in Georgia.

Other nurse practitioner in Toccoa

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →